miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1

BACKGROUND: Sorafenib can prolong the survival of patients with advanced hepatocellular carcinoma (HCC). However, drug resistance remains the main obstacle to improving its efficiency. This study aimed to explore the likely molecular mechanism of sorafenib resistance. METHODS: Differentially express...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Transl Med
Autors principals: Tan, Wenliang, Lin, Zhirong, Chen, Xianqing, Li, Wenxin, Zhu, Sicong, Wei, Yingcheng, Huo, Liyun, Chen, Yajin, Shang, Changzhen
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7859776/
https://ncbi.nlm.nih.gov/pubmed/33553331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-2081
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars